Oramed Pharmaceuticals Inc. (ORMP) Shares Up 4.4%
Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) shot up 4.4% during mid-day trading on Thursday . The stock traded as high as $8.82 and last traded at $8.25, with a volume of 171,160 shares. The stock had previously closed at $7.90.
Several brokerages have issued reports on ORMP. Aegis reaffirmed a “buy” rating and set a $18.00 price target on shares of Oramed Pharmaceuticals in a research note on Wednesday, May 18th. FBR & Co lifted their price target on Oramed Pharmaceuticals from $15.00 to $20.00 and gave the stock an “outperform” rating in a research note on Thursday, May 26th. Finally, Rodman & Renshaw reaffirmed a “buy” rating and set a $25.00 price target on shares of Oramed Pharmaceuticals in a research note on Friday, May 13th. Five analysts have rated the stock with a buy rating, Oramed Pharmaceuticals currently has an average rating of “Buy” and an average price target of $22.00.
The company’s market cap is $105.61 million. The company has a 50-day moving average of $8.17 and a 200-day moving average of $7.68.
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.